The PP405 news are the best news we've had in the last 20 or more years.
    6/17/2025

    From the encyclopedia
    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    At a glance
    In this research discussion post, the primary subjects mentioned are
    • PP405 4 weeks
    • Finasteride 1 year
    the tone is 😀 positive with significant improvement results.

    Other terms

    PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.